Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19

Mild to Moderate COVID-19 Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of RAY1216 Tablets in Patients With Mild to Moderate SARS-CoV-2 Infection

Status Completed

Clinical Trial Summary

This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of RAY1216 tablets in the treatment of mild to moderate SARS-CoV-2 infection. The total study duration is up to 28 days.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05620160
Study type	Interventional
Source	Guangdong Raynovent Biotech Co., Ltd
Contact
Status	Completed
Phase	Phase 3
Start date	November 12, 2022
Completion date	March 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04705844` - Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)	Phase 3
Recruiting	`NCT05941793` - A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients	Phase 2
Terminated	`NCT04521296` - Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo	Phase 2/Phase 3
Completed	`NCT05582629` - JT001 (VV116) for the Treatment of COVID-19	Phase 3
Recruiting	`NCT06197217` - Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19	Phase 3
Recruiting	`NCT05675072` - Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19	Phase 2/Phase 3
Terminated	`NCT05242042` - JT001 (VV116) for the Early Treatment of COVID-19	Phase 2/Phase 3
Suspended	`NCT04711863` - Fluvoxamine for Adults With Mild to Moderate COVID-19	Phase 2